Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5982-5991
DOI: 10.1111/dom.70769 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 23.04.2026. Verfasst von Rune Viig Overgaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Søborg, Denmark. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Obesity. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Semaglutide has previously been approved for weight management and cardiovascular disease as a subcutaneous formulation, and more recently also as an oral formulation. However, there is limited information across oral dose levels, and there are no studies for the 25 mg dose in people with obesity and type 2 diabetes (T2D). To fulfil health authority approval requirements, population pharmacokinetic and exposure–response analyses were used to extrapolate efficacy and safety data from subcutaneous to oral semaglutide. Materials and Methods Once‐daily oral semaglutide 25 mg was approved for obesity treatment based on historical semaglutide data and the OASIS programme. Two studies were simulated: a modelled/virtual Phase 2 trial to establish efficacy across different oral semaglutide dose levels, and a modelled/virtual Phase 3 trial to assess efficacy in a population with overweight/obesity and T2D.
Results
Most participants (82.2%) treated with oral semaglutide 25 mg in OASIS 4 achieved exposure levels within the same range as participants treated with once‐weekly subcutaneous semaglutide 2.4 mg in STEP 1. In the simulated studies, oral semaglutide 25 mg provided significantly greater weight reduction compared with placebo, for the trial product estimand and treatment policy estimand, respectively, in those with overweight/obesity and T2D (9.4% and 7.8%), and in those with overweight/obesity without T2D (16.3% and 14.7%).
Conclusions
Estimated exposure levels and efficacy observed with oral semaglutide 25 mg were similar to those obtained with subcutaneous semaglutide 2.4 mg, supporting application of oral semaglutide 25 mg to treat individuals with overweight/obesity, with/without T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Novo Nordisk A/S, Søborg, Denmark.
- University of Toronto, York University, McMaster University, Wharton Weight Management Clinic, Burlington, Ontario, Canada.
- Washington Center for Weight Management and Research, Arlington, Virginia, USA.
ORCID-Profile: Rune Viig Overgaard, Oscar Birkhan, Anders Strathe, Sean Wharton
Förderung
- Novo Nordisk A/S
Zitieren
APA
Overgaard, R. V., Birkhan, O., Rathor, N., Sparsø, T., Strathe, A., Wharton, S., & Rubino, D. (2026). Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach. Diabetes, Obesity and Metabolism, 28(7), 5982-5991. https://doi.org/10.1111/dom.70769
Vancouver
Overgaard RV, Birkhan O, Rathor N, Sparsø T, Strathe A, Wharton S, et al. Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach. Diabetes, Obesity and Metabolism. 2026;28(7):5982-5991. doi:10.1111/dom.70769
BibTeX
@article{Overgaard2026,
author = {Overgaard, Rune Viig and Birkhan, Oscar and Rathor, Naveen and Sparsø, Thomas and Strathe, Anders and Wharton, Sean and Rubino, Domenica},
title = {Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {5982--5991},
doi = {10.1111/dom.70769}
}
EUVIMED